A comprehensive view of Combination Therapy. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

CARsgen Therapeutics partners with Roche to assess CARsgen's investigational drug AB011 combined with Roche’s atezolizumab, standard-of-care chemotherapy to treat gastric or gastroesophageal junction cancer; Roche to handle operations, clinical trial
Published: February 01, 2023 by MarketLine
US Patent Issued to Eli Lilly and Co. on Jan. 31 for "Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer" (Indiana Inventors)
Published: February 01, 2023 by U.S. Fed News
US Patent Issued to Five Prime Therapeutics, Bristol-Myers Squibb on Jan. 31 for "Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers" (California, Washington Inventors)
Published: February 01, 2023 by U.S. Fed News
INTERNATIONAL PATENT: BIONTECH SE, GENMAB A/S FILES APPLICATION FOR "MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN COMBINATION THERAPY FOR CANCER"
Published: January 23, 2023 by U.S. Fed News
AIM ImmunoTech enters into clinical research agreement with AstraZeneca and Erasmus Medical Center in the Netherlands; study to evaluate AIM’s Ampligen rintatolimod in combination with AstraZeneca’s Imfinzi durvalumab to treat pancreatic cancer
Published: January 17, 2023 by Proactive Investors

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count